Chen Tao, Zhang Yang, Ding Liting, Xiong Chenlu, Mei Chao, Wei Sisi, Jiang Ming, Huang Yingjie, Chen Jianrong, Xie Tao, Zhu Qing, Zhang Qi, Huang Xuan, Chen Shibiao, Li Yong
Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China.
The National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Provincial Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College Nanchang University Nanchang China.
MedComm (2020). 2025 Apr 22;6(5):e70149. doi: 10.1002/mco2.70149. eCollection 2025 May.
Acute kidney injury (AKI) is a prevalent and serious clinical disease with a high incidence rate and significant health burden. The limited understanding of the complex pathological mechanisms has hindered the development of efficacious therapeutics. Tripartite motif containing 65 (TRIM65) has recently been identified as a key regulator of acute inflammation. However, its role in AKI remains unclear. The present study observed that TRIM65 expression was upregulated in AKI. Moreover, the knockout of the gene in mice exhibited a substantial protective impact against rhabdomyolysis, ischemia-reperfusion (I/R), and cisplatin-induced AKI. Mechanistically, TRIM65 directly binds and mediates K48/K63-linked polyubiquitination modifications of voltage-dependent anion channel 1 (VDAC1) at its K161 and K200 amino acid sites. TRIM65 plays a role in maintaining the stability of VDAC1 and preventing its degradation by the autophagy pathway. TRIM65 deficiency attenuates mitochondrial dysfunction in renal tubular epithelial cells during AKI. Conversely, the overexpression of VDAC1 in renal tissues has been demonstrated to negate the protective effect of TRIM65 deficiency on AKI. These findings suggest that TRIM65 may play a role regulating of AKI through the targeting of VDAC1-dependent mitochondrial function, offering potential avenues for the development of new drug targets and strategies for the treatment of AKI.
急性肾损伤(AKI)是一种常见且严重的临床疾病,发病率高,健康负担重。对其复杂病理机制的了解有限,阻碍了有效治疗方法的开发。含三联基序蛋白65(TRIM65)最近被确定为急性炎症的关键调节因子。然而,其在AKI中的作用仍不清楚。本研究观察到AKI中TRIM65表达上调。此外,在小鼠中敲除该基因对横纹肌溶解、缺血再灌注(I/R)和顺铂诱导的AKI具有显著的保护作用。机制上,TRIM65直接结合并介导电压依赖性阴离子通道1(VDAC1)在其第161和200位氨基酸位点的K48/K63连接的多聚泛素化修饰。TRIM65在维持VDAC1的稳定性和防止其通过自噬途径降解中发挥作用。TRIM65缺乏可减轻AKI期间肾小管上皮细胞的线粒体功能障碍。相反,肾组织中VDAC1的过表达已被证明可消除TRIM65缺乏对AKI的保护作用。这些发现表明,TRIM65可能通过靶向VDAC1依赖性线粒体功能在AKI调节中发挥作用,为开发新的药物靶点和AKI治疗策略提供了潜在途径。